spotlight innovation
spotlight innovation subsidiary celtic biotech iowa receives approval to commence phase i part 2 clinical trial of crotoxin: : spotlight innovation inc. (stlt )
spotlight innovation subsidiary celtic biotech iowa granted patent by the u. s. patent and trademark office: : spotlight innovation inc. (stlt )
spotlight innovation subsidiary celtic biotech iowa, inc. completes merger with celtic biotech ltd .
spotlight innovation inc. : other events, financial statements and exhibits (for. .
spotlight innovation subsidiary celtic biotech iowa granted patent by the u. s. patent and trademark office
march 13, 2018 newly issued u. s. patent covers spotlight innovation’s spinal muscular atrophy drug candidates
press contact rene erickson spotlight innovation inc. 1 - 515 - 274 - 9087 corpcomm @ urltoken investor relations contact mike reysack spotlight innovation inc. 1 - 641 - 512 - 1035 investor. relations @ urltoken
stlt stock price - spotlight innovation inc. stock quote (u. s. : otc) - marketwatch
press contact rene erickson spotlight innovation, inc. 1 - 505 - 274 - 9087 corpcomm @ urltoken investor relations contact mike reysak spotlight innovation, inc. 1 - 505 - 274 - 9087 investor. relations @ urltoken
celtic biotech iowa, inc. is a subsidiary of spotlight innovation, inc. additional information available at urltoken .
spotlight innovation inc. (otcmkts: stlt) files an 8 - k other events item 8. 01 other events .
the post spotlight innovation inc. (otcmkts: stlt) files an 8 - k other events appeared first on market exclusive .
spotlight innovation does not currently have any hardcopy reports on annualreports. com. click the button below to request a report when hardcopies become available .
on june 20, 2018, spotlight innovation inc. issued a company overview that it plans to present to potential and existing investors. a copy of this company overview is furnished as exhibit99. 1 hereto and is incorporated herein by reference. the company overview is also posted on spotlight innovation inc.' s website at urltoken
west des moines, ia - - (marketwired - jun 10, 2014) - spotlight innovation, inc. (otcqb: stlt) today announced that effective june 4, 2014, celtic biotech iowa, inc. (a subsidiary of spotlight innovation, inc .) has completed a share exchange agreement with biopharmaceutical company celtic biotech ltd .
spotlight innovation inc. today announced that it has formed a corporate partnership with university of iowa athletics that will provide ongoing radio and digital media visibility for the venodol brand ...
pursuant to the share exchange agreement, celtic biotech ltd. is a subsidiary of celtic biotech iowa, inc. , and gains access to spotlight innovation' s intellectual property commercialization and business development expertise .
as of last trade, spotlight innovation inc (stlt: qbb) traded at 0. 0245, 29. 63% above the 52 week low of 0. 0189 set on jul 05, 2018 .
spotlight innovation inc. is a pharmaceutical company. the company is focused on acquiring the intellectual property rights to therapeutics designed to address unmet medical needs. as of june 30, 2017, the company had four su
urbandale, ia, april 18, 2018 - - spotlight innovation inc. , a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that company subsidiary celtic biotech iowa, inc. , reported ...
spotlight innovation, inc. is a bioscience company, which engages in acquiring the rights and license to proprietary technologies. it operate through its subsidiaries, which identifies and targets technology candidates including cancer drugs and treatment therapies ...
the fact that we have always hungered for innovation is evident from the history of human kind. this hunger for progress also explains why innovation is the driving force behind economic growth. as innovation transforms the way we live, work and do business, what can we learn from organisations that are harnessing its power most effectively ?
urbandale, iowa, aug. 16, 2017 / prnewswire / - - spotlight innovation inc. (stlt) today announced that the company has entered into a sponsored research agreement with indiana university to support research directed by elliot androphy, m. d. , aimed at developing safe and effective drugs to treat patients with spinal muscular atrophy (sma). dr. androphy is a member of spotlight innovation' s scientific advisory board and a co - inventor of stl - 182, the company' s lead product candidate for sma. geoffrey laff, ph. d. , spotlight innovation' s senior vice president of business development, commented ,
dr. androphy is a prolific researcher and highly - respected thought leader .
the johnson family’s commitment to innovation and frank lloyd wright’s visionary design have gone hand in hand for nearly 80 years. at our campus, visitors can experience a rich history of exploration and innovation in architecture that has drawn increasing global interest .
cris grunewald, president and ceo of spotlight innovation, said ,
we are extremely pleased to be moving forward with memcine pharmaceuticals' innovative team and technology. memcine pharmaceuticals' immunoplex technology has shown enormous potential with broad applicability in both infectious diseases and oncology immunotherapy. memcine pharmaceuticals' mission directly supports spotlight innovation' s goal of positively impacting the health and well - being of as many people as possible, and we look forward to furthering the development and fulfilling the promise of this exciting, potentially life - saving technology .
unleashing the power of innovation within the organisation is ultimately the role of the ceo. recognising this, ceos are now taking personal responsibility for directing and inspiring innovation. they’re creating leaders at every level and in every pocket of the organisation to make sure that innovation is not just viewed as the preserve of the chief information officer or research and development. our fast takes on talent innovation series explains that the most successful companies are those that create an environment ‘where the ideas and innovations come from everyone’ .
/ prnewswire / - - spotlight innovation inc. (otcqb: stlt) announced today that its subsidiary celtic biotech iowa has received approval from the french national agency for the safety of medicines and health products (ansm) to commence part 2 of its phase i dose escalation safety study ,
previous global innovation 1000 studies have long confirmed that when it comes to innovation, it’s not how much you spend, but how you spend it that matters. now it’s also case that where you spend can help to determine your success. innovation could effectively lead to a transformative shake - up of the world order, as we know it – and it might happen sooner than we think .
said tony vanden bush, phd, co - founder, co - inventor, director and chief scientific officer of memcine pharmaceuticals ,
we are excited to be working with spotlight innovation to move the immunoplex platform technology through development and toward clinical use for infectious disease prevention and personalized cancer immunotherapeutics .
organisations must continually innovate if they want to drive rapid and profitable revenue growth. nearly half (43 %) of executives surveyed by pwc for our breakthrough innovation and growth report said that innovation was a ‘competitive necessity’ for their organisation. what’s more, the vast majority (93 %) indicated that organic growth through innovation would be the biggest contributor to their organisation’s revenue growth over the next five years .
the museum also will feature interactive exhibits tied to innovation, driven in part through a $ 10 million donation from urltoken founder jeff bezos. durbin was a bit mum on the plans for the bezos - backed “center for innovation, ” which will open in the fall of 2013 .
from lister’s antiseptic system, to 3d printing organs to assist surgeons in planning complex operations, king’s has contributed significantly to surgical and medical innovation .
a partial report preview for spotlight innovation inc is shown below. where indicated by
yes ,
creditriskmonitor contains this information in its extensive database. to get access to the full report and learn more about creditriskmonitor' s robust financial risk analysis and timely news service, request a personalized demo and free trial today .
west des moines, ia: spotlight innovation – a provider of solutions for healthcare - focused companies, has announced that its subsidiary celtic biotech iowa –a developer of novel clinical trial - phase therapeutic products for the treatment of cancers and pain in humans has entered into an exclusive, world - wide (excluding china) license agreement .
spotlight innovation, inc. provides solutions for healthcare - focused companies commercializing healthcare intellectual property developed by major centers of academia in the united states. the company focuses on identifying, validating and acquiring / cooperating with early stage companies developing healthcare technologies including pharmaceuticals, devices and equipment, diagnostic products and healthcare it. additional information available at urltoken .
urbandale, iowa, july 11, 2017 / prnewswire / - - spotlight innovation inc. (stlt) today announced that its subsidiary caretta therapeutics, llc, has engaged transmedia group to provide public relations support for venodol, a new over - the - counter, non - addictive alternative to opioid and steroidal analgesics that is tentatively scheduled to be available in the united states in summer 2017 .
the transmedia team' s proven track record of generating consumer enthusiasm for products in the over - the - counter category makes them highly qualified to manage the product launch and to implement a product awareness strategy for venodol ,
said john krohn, spotlight innovation' s president and chief executive officer .
, spotlight innovation' s president and chief executive officer, said ,
we invested significant time and effort to advance our treatment paradigm using the results of part 1. we are very pleased that our part 2 protocol was accepted and approved by ansm. this marks a significant milestone for crotoxin as it enters the next stage of clinical testing .
mr. grunewald is president and ceo of spotlight innovation inc. he is an entrepreneur and financial executive with backgrounds in the healthcare and biotechnology sectors, private equity and investment banking. mr. grunewald has been involved in all stages of the commercialization of healthcare intellectual property developed by premiere research and development institutions. prior to spotlight innovation, mr. grunewald served as vice president with an institutional healthcare business incubator where he performed comprehensive operational roles in the formation and development of companies commercializing medical device, it service and therapeutic drug ip. mr. grunewald received a bachelor of science from iowa state university, and served as a united states marine topographical intelligence specialist, receiving extensive military intelligence training from the national geospatial - intelligence agency .
the university of cambridge has signed an agreement with one of china’s largest universities to encourage innovation and entrepreneurship in one of china’s fastest - growing high - tech clusters .
spotlight innovation subsidiary caretta therapeutics’ over - the - counter chronic pain relief product, venodol roll - on, is now available online at urltoken, urltoken and urltoken. venodol roll - on topical analgesic is formulated to provide long - lasting relief from chronic pain associated with inflammation, including joint pain, tendinitis, arthritis (excluding osteoarthritis), and stubborn body aches .
spotlight innovation, inc. is a bioscience company, which engages in acquiring the rights and license to proprietary technologies. it operate through its subsidiaries, which identifies and targets technology candidates including cancer drugs and treatment therapies for disease states, and drug and treatment therapies for infectious diseases. the company was founded on december 12, 2013 and is headquartered in urbandale, ia .
mr. cristopher grunewald, spotlight innovation' s president and chief executive officer, said ,
we invested significant time and effort to advance our treatment paradigm using the results of part 1. we are very pleased that our part 2 protocol was accepted and approved by ansm. this marks a significant milestone for crotoxin as it enters the next stage of clinical testing .
cris grunewald, president and ceo of spotlight innovation, stated ,
we are creating and protecting value for crotoxin as we progress through clinical efficacy trials. the legal protection afforded by the exclusivity of a u. s. patent is an important component of our commercialization strategy for crotoxin, and a significant step in our value - building strategy for celtic biotech iowa .
competition for talent helps to explain why innovation has become a truly global activity. our most recent global innovation 1000 research discovered that the overwhelming majority (94 %) of the world’s largest innovators carry out part of their research and development programmes abroad. innovation spending has boomed in china and india since 2008 and more r & d is now conducted in asia than in north america or europe. the research also found that businesses with a more global r & d footprint outperformed their less globalised competitors on a variety of financial measures .
the integration of science in to technology and in to healthcare has really improved patient care. i’m pleased to say that king’s has been at the forefront of some of that innovation .
about celtic biotech iowa inc. celtic biotech iowa inc. , a subsidiary of spotlight innovation inc. , has developed novel, clinical trial - phase therapeutic products for the treatment of cancers and pain in humans. derived from naturally specialized receptor - binding proteins, these products have the potential to reduce treatment costs, increase survivability, and improve the quality of life for cancer patients. additional information available at urltoken .
west des moines, ia - - (marketwired) - - 01 / 15 / 15 - - spotlight innovation inc. (otcqb: stlt) announces that its subsidiary celtic biotech iowa inc. has been granted u. s. patent entitled crotoxin administration for cancer treatment and pain relief. the invention relates to crotoxin compositions for intravenous administration and methods of use of crotoxin for the treatment of pain and / or for the treatment of neurologic and neuromuscular disorders .
spotlight innovation inc. (otcqb: stlt) announces today that it completed the acquisition of a majority ownership in memcine pharmaceuticals inc. , located at the university of iowa research park in coralville, iowa. memcine pharmaceuticals is developing its immunoplex™ vaccine platform technology, which is designed to use the body' s own naturally occurring targeting system to deliver vaccine components to immune cells and stimulate a robust response. memcine pharmaceuticals has a licensing agreement for its technologies with the university of iowa .
pankaj chandak was awarded the british science association’s lecture for agricultural, biological and medical sciences. you can book to attend the public lecture, entitled ‘from kings to keyholes: surgical innovation in organ transplantation’, online at urltoken
spotlight innovation inc. (otcqb: stlt) acquires and develops proprietary therapies to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. the company identifies in - licensing opportunities and manages product development through partnerships with universities, medical schools, contract research organizations (cros), and contract manufacturing organizations (cmos). at the appropriate stage of research and development the company will endeavor to pursue product commercialization opportunities including, but not limited to, out - licensing and strategic partnerships with industry leaders .
seattle’s history is very much tied to innovation, whether it’s bill boeing’s early aircraft or bill gates’ early software. and those breakthrough technologies — as well as dozens of others — are on full display at seattle’s new museum of history and industry .
cristopher grunewald, president and ceo of spotlight innovation and director of celtic biotech iowa, said ,
celtic biotech iowa' s mission directly supports our goal of positively impacting the health and well - being of as many people as possible. celtic biotech ltd.' s novel, development - stage cancer and pain therapeutic products for treatment in humans, derived from naturally specialized receptor - binding proteins, have the potential to reduce treatment costs, increase survivability, and improve the quality of life for cancer patients. we look forward to fulfilling their promise .
spotlight innovation inc. , incorporated on may 11, 2006, is a pharmaceutical company. the company is focused on acquiring the intellectual property rights to therapeutics designed to address unmet medical needs. as of june 30, 2017, the company had four subsidiaries: celtic biotech iowa, inc. (celtic iowa), caretta therapeutics, llc (caretta), sma therapeutics, llc (sma), and zika therapeutics, llc (zika). it is focused on various diseases, including cancer, pain management, zika virus infection and spinal muscular atrophy .
recording and collecting the work of inventors has long been a mission of the smithsonian. the lemelson center of the national museum of american history documents, interprets, and disseminates information about invention and innovation, and fosters an appreciation for the central role invention and innovation play in the history of the united states. the national air & space museum explores the invention, history, science, and technology of aviation and space flight. the anacostia museum has a special exhibit: the real mccoy, african - american invention and innovation, 1619 - 1930 and the remembering gallery' s exhibit: american inventors and inventions. here we examine a handful of famous amercan inventors, some like benjamin franklin, who are well known for their creations, others such as thomas jefferson, who are better known for other contributions .
innovation is about the application of new ideas, discoveries and inventions. at the university of cambridge, the recipe for success has been ingenuity and creativity, alongside the fundamental research that underpins these ideas, and combined with the constant exchange of ideas between academics and companies, governments and ngos .
west des moines, iowa, nov. 10, 2016 / prnewswire / - - spotlight innovation inc. (otcqb: stlt) announced today that its subsidiary celtic biotech iowa has received approval from the french national agency for the safety of medicines and health products (ansm) to commence part 2 of its phase i dose escalation safety study, crotoxin in patients with advanced cancer using an intravenous route of administration. the ansm, a healthcare regulatory agency, acts on behalf of the french government to ensure patient safety. the clinical study will be conducted at pitié - salpêtrière hospital in paris. noted french oncologist david khayat, md, phd, fasco, is the principal investigator .
the 15 - story research tower is the birthplace of some of the company’s most iconic, trusted brands; like raid®, glade®, pledge® and off! ®. while it hasn’t been in active use for 30 years, the research tower still remains a visible reminder of the great spirit of innovation that continues to drive the company .
urbandale, iowa, aug. 7, 2017 / prnewswire / - - spotlight innovation inc. (stlt), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that its subsidiary caretta therapeutics' new over - the - counter chronic pain relief product, venodol roll - on, is now available for pre - order in the u. s. at venodol. com. venodol roll - on is a topical analgesic formulated to provide long - lasting relief from chronic pain associated with inflammation, including joint pain, tendinitis, arthritis (excluding osteoarthritis), and body aches. in the coming months caretta therapeutics plans to introduce additional venodol product formats and to expand distribution to mass merchandise retailers through its master broker agreement with a premier global distribution brokerage firm .
as far as innovative cultures go, it’s hard to beat silicon valley right now. what distinguishes silicon valley firms from other companies is their ability to integrate their innovation strategies with their business strategies. these firms identify their customers’ actual needs, figure out how to meet those needs and then get the necessary product or service to market as fast as possible .
due to the huge disruption that digital technology is bringing to every sector, innovation has to some extent become synonymous with digital transformation. pwc’s report, industry 4. 0: building the digital enterprise, reveals that industrial and manufacturing companies are digitising every aspect of their businesses, from their product development and purchasing processes through to the way in which they serve their customers. they are investing around 5% of their annual revenues to achieve this, spending us $ 907bn every year through to 2020. but successful innovation isn’t just about digital technology. as industry 4. 0 explains, it also depends on an organisation’s ‘ digital iq ’ – how its people, processes and business model respond to opportunities in this era of rapid transformation .
today, this patient - centered approach and spirit of innovation continues to drive ventana forward. it inspires us to continuously innovate pathology by improving laboratory efficiency and by generating new assays to address unmet medical needs. through the use of automation, laboratory turnaround times have decreased from several weeks to a few days. patients and their physicians spend less time waiting for results, and more time fighting the disease .
spotlight innovation inc. , formerly american exploration corporation, is a bioscience company. the company is focused on acquiring the rights, through acquisition, license or otherwise, to various technologies. the company is engaged in identifying and targeting technology candidates, including cancer drugs and treatment therapies for various disease states; drug and related treatment therapies for various infectious diseases, and other technology candidates. the company focuses on diseases that are rare, which are known as orphan diseases, or new or common but underserved, such as feline chronic kidney disease. as of december 31, 2015, the company had three subsidiaries: celtic biotech iowa, inc. , cdt veterinary therapeutics, inc. and memcine pharmaceuticals, inc. through its subsidiary, celtic biotech iowa, inc. , it develops a range of drug candidates, such as crotoxin, cardiotoxin, vrctc310 and crotamine. through its subsidiary, memcine pharmaceuticals, inc. , it offers immunoplex .
leadership and culture are particularly important given that innovation is becoming more radical. our survey cited above, found that the way in which companies innovate is being transformed as ceos look for solutions that offer entirely new sources of revenue, rather than just better products. an example might be a soap powder manufacturer that decides to open up a chain of launderettes or an engine maker that moves from selling engines to charging users for running them .
on march 29, 2016, management of spotlight innovation inc. , with the approval of the board of directors concluded that the previously issued financial statements contained in the company' s quarterly reports on form 10 - q for the quarters ended june 30, 2014, september 30, 2014, march 31, 2015, june 30, 2015 and september 15, 2015 and in the annual report on form 10 - k for the year ended december 31, 2014 should no longer be relied upon because of an error in recording the value of intellectual property assets acquired in a transaction between the company and celtic biotech ltd. , an irish limited company, that closed on june 4, 2014. in the financial statements included in the forms 10 - q and form 10 - k for the prior periods, the company recorded intellectual property assets of $ 6, 977, 347 related to the transaction. a subsequent valuation report dated march 29, 2016 indicated that the value that should have been recorded during the prior periods under generally accepted accounting principles should have been $ 415, 579 .
to foster innovation in storytelling, we identified the need to cultivate the tools necessary to deliver cross - media storytelling. one of the great advantages of leveraging cross - media and non - linear storytelling principles is the creation of multiple entry points to a particular subject or theme. selection of key emerging technologies allow us to bring attention to those entry points for multi - generational audiences. in addition, creating such methodologies through technology often provides the necessary hooks for media agencies to publicize or otherwise report stories involving themes and content that the museum is seeking to bring to the public’s attention .
in comparison to the in - gallery visitation, online engagement was mostly focused on a single platform. out of approximately 3, 300 downloads, ios and android only made up 6% and 3% respectively. gear vr captured a niche audience 10 times larger than vr on ios and android. in early analysis, it appears that part of that outcome can be attributed to the number of apps available in the oculus store versus itunes or google play. in the month previous to the exhibition opening, there were only 300 apps available in the gear vr (oculus vr, 2016). weaving a better future was featured by oculus in an e - mail to its press contacts of new apps released. through leveraging an emerging platform, the opportunity to have a spotlight on the project resulted in finding an increased audience and more meaningful visitor experience .
the agreement focuses on developing and marketing a patent - pending invention related to the treatment of acute and chronic nephropathy, use of cardiotoxin for the treatment of chronic kidney disease (ckd). animal studies have shown that cardiotoxin has the ability to inhibit the immune processes that damage the kidneys. this will help to reduce the level of proteinurea, serum creatinine and urea in chronic
this ckd therapy has shown the potential to improve kidney function in a variety of animal models, and we expect to see comparable effectivity as we move this therapy through the clinical trial process. for those people who have experienced kidney failure due to chronic kidney disease, there are currently only two options for treatment - - life - long dialysis or kidney transplant. we would hope that this therapy could be utilized to delay or stop the progression to dialysis or surgery, ” says dr. paul reid, president, celtic biotech iowa .
by anthony g. dupree, cio and ciso, novitex enterprise ...
by jeffrey t pollock, vp - product management, oracle [ nyse: ...
by david pollino, deputy chief security officer, svp, bank ...
copyright © 2018 cioreview. all rights reserved. contact | subscribe | advertise with us
for inquiries related to this message please contact support. for sales inquiries, please visit urltoken
if you believe this to be in error, please confirm below that you are not a robot by clicking
i' m not a robot
below .
please make sure your browser supports javascript and cookies and that you are not blocking them from loading. for more information you can review the terms of service and cookie policy .
“there are no poisons, only poisonous doses. ” thus did paracelsus, the greatest of the alchemists, encapsulate an important piece of medical wisdom. in fact, that is only half the story, for many materials which are toxic at high doses, when used sparingly and directed at specific targets, are not merely harmless, but actually beneficial. plant poisons, from digitalis to curare, are routinely employed as drugs. and now it is the turn of animal toxins, as researchers examine venoms secreted by snakes and lizards, to see if they, too, might be turned into treatments .
snake venom, collected from farmed reptiles, has been used to make antisera for snake bites for decades by injecting it into mammals such as sheep and horses, and collecting the antibodies thus generated. making drugs from the venom itself, however, is a fairly new idea. but that is what stefan hailey of the university of delaware and his colleagues hope to do. in a paper published recently by toxicon, they report how a protein called eristostatin, which can be extracted from the venom of the asian sand viper, helps people’s immune systems fight malignant melanoma. previous studies have shown that eristostatin stops melanoma cells colonising the liver and lungs in mice. dr hailey is trying to work out how this happens .
eristostatin’s day job is to stop victims’ blood clotting and thus plugging up damaged blood vessels after a bite. by increasing blood loss, it weakens victims. the molecule does this by glomming onto cellular fragments called platelets that are crucial to the process of clotting, thus disabling them. dr hailey hopes to make use of this tendency to encourage the immune system to attack melanoma cells. his idea requires eristostatin to be as attracted to cancer cells as it is to platelets .
two observations suggest it could be. one is that eristostatin has a particular affinity for melanoma cells, which presumably have a protein on their surfaces that is similar to the one which attracts eristostatin to platelets. the other observation is that when eristostatin is attached to a cell’s surface it attracts the attention of t - lymphocytes. these are immune - system cells whose job is to kill other body cells that have been infected with viruses, or which have turned cancerous. if melanoma cells could, in this way, be made especially attractive to t - lymphocytes, that might clear away the tumour completely .
dr hailey and his colleagues used a technique called atomic - force microscopy to study the interactions between melanoma cancer cells and eristostatin. this technique allows the force required to pull the two apart to be measured precisely, to see whether there is a genuine attraction—which he found that there is .
if eristostatin does prove an effective means to treat cancer, it will join a growing stable of medicines derived from reptile toxins. tirofiban, for instance, is a modified version of another anticoagulant—in this case from the venom of the african saw - scaled viper. it is given to people with angina, and also to those who have had heart attacks. exenatide is the synthetic form of a hormone called exendin - 4 that occurs naturally in the saliva of the gila monster, a venomous north american lizard. it works as a treatment for type - 2 diabetes because it increases insulin production in those whose blood - sugar levels are high. and captopril, a blood - vessel - relaxing agent widely used to treat hypertension, is based on teprotide, from brazilian arrowhead vipers, which helps the other toxins in the venom circulate quickly, and thus reach their targets rapidly .
there are other venom - based drugs in the pipeline, too. crotoxin, a protein from the south american rattlesnake, though not yet approved for use, may one day be employed to treat cancers. crotoxin seems particularly attracted to cancer cells. one portion of the molecule recognises a protein on the cell’s membrane, and links to it. the other portion damages the membrane, triggering a mechanism called apoptosis which causes the cell to kill itself. celtic biotech, based in dublin, is running a series of tests using this molecule on cancer patients at the georges pompidou european hospital in paris. this year, celtic plans to try it on people with several different sorts of cancer, since the firm’s researchers believe it should be effective on all solid tumours. if those trials are successful, though, they then plan to concentrate on lung cancer, the largest market .
perhaps the most astonishing toxin - derived drug of all, however, is hannalgesin, which is made from king - cobra venom. kini manjunatha of the national university of singapore is developing this substance as a pain - relieving agent. he claims it is between 20 and 200 times more effective than morphine. moreover, unlike morphine, which is usually injected, hannalgesin can be taken by mouth. he is planning to run the first clinical trials at the end of 2013 or in early 2014 .
venom, then, is proving to be a trove of useful molecules. at a time when drug companies are struggling to develop new products, a novel source of raw materials that have been road - tested by natural selection, and merely need to be subverted from their original purposes rather than created afresh, must be welcome. it is not turning base metals into gold, as paracelsus and his kind once attempted. but as a transformation of matter, it is surely a far more valuable trick .
each week, over one million subscribers trust us to help them make sense of the world .
published since september 1843 to take part in “a severe contest between intelligence, which presses forward, and an unworthy, timid ignorance obstructing our progress. ”
we use cookies to personalise content, target and report on ads, to provide social media features and to analyse our traffic .
an irish biotech company will this week begin human trials of a new cancer treatment derived from rattlesnake venom .
celtic biotech, founded in 2003 by businessmen john reid and dr paul reid, has developed a treatment for advanced cancer from a powerful protein found in rattlesnake venom .
the company will this week begin testing the drug, now known as cb24, on patients at the george pompidou university hospital, paris, under the supervision of consultant cancer specialist jacques medioni .
celtic biotech expects the trials to last about a year. they are designed to highlight the therapeutic value and safety of the drug .
the irish company discovered a protein in rattlesnake venom that causes malignant cancer cells to self - destruct, a process known as cell death .
two independent studies, by the us national cancer institute and university of texas md anderson cancer center, have confirmed the protein’s anti - cancer properties .
celtic biotech has been researching this for the last seven years and made a number of breakthroughs during that time. it has applied for a number of patents and highlighted its findings in scientific journals .
former assistant us surgeon general, dr roscoe moore jnr, who is on celtic biotech’s scientific board of advisers, says that cb24 provides a “promising approach” .
dr paul reid has a degree in microbiology from trinity college dublin and a masters in neurobiochemistry from imperial college, london. john reid has a masters in management from trinity college dublin .
the company maintains its own colony of breeding rattlesnakes in the us. rattlesnakes are found throughout north america, from southern canada to mexico. they are responsible for more than 80 per cent of snake bite fatalities in the us, and the vast majority of snake bite injuries .
however, they only attack when provoked and the bites are rarely fatal if treated quickly .
about one in four people in industrialised countries are likely to contract cancer within their lifetime. the world health organisation says that the disease killed about 7. 8 million people in 2008 .
html public
- / / w3c / / dtd xhtml 1. 0 transitional / / en
urltoken
an irish biotech company has developed a treatment for advanced cancer using a powerful protein found in rattlesnake venom and will begin human trials of the treatment this week, reports the irishtimes. celtic biotech, founded in 2003 by businessmen john reid and dr paul reid, discovered the protein, which causes malignant cancer cells to self - destruct, and has been researching the protein' s anti - cancer properties for the last seven years. it has applied for a number of patents and has highlighted its findings in scientific journals .
read more: belfast scientists make major breakthrough in prostate cancer fight megan malone set to receive all clear from cancer after u. s. treatment two independent studies, by the us national cancer institute and university of texas md anderson cancer center, have confirmed the protein' s anti - cancer properties. celtic biotech will begin testing the drug known as cb24 on patients at the george pompidou university hospital in paris, under the supervision of consultant specialist jacques medioni. former assistant us surgeon general, dr roscoe moore jnr, who is on celtic biotech’s scientific board of advisers, says that cb24 provides a “promising approach .
an irish company is using four american diamondback rattlesnakes in a new clinical trial that will test snake venom as a treatment for cancer. the snakes, which hail from the albuquerque biopark, will be allowed to bite something and have their venom extracted humanely. the venom contains proteins that will be extracted and refined to target and kill cancer cells .
snake venom has long shown promise as a treatment for cancer, in a wide range of animal trials dating back several years. celtic biotech isolated a protein in a type of rattlesnake venom that causes malignant cancer cells to commit cell suicide. the company developed a venom - derived drug called cb24 and started testing it on humans at the end of october, working with patients at the george pompidou university hospital in paris. the trial is expected to last a year, and is designed to prove cb24' s safety and therapeutic value, according to celtic biotech .
the company has already tested it in mice and in human cell lines with great success. other institutions in the u. s. have independently verified cb24' s anti - cancer properties, the company says .
the four albuquerque diamondbacks were sent to the kentucky reptile zoo last week, according to the biopark. there, specially trained reptile curators will extract the snakes' venom and ship it to paris .
snake venom is potent not only as a paralytic agent and neurotoxin but also as a cancer treatment, celtic biotech says — a little goes a long way. the protein is derived from crotoxin, which apparently has some targeting abilities as well as toxicity. this makes it particularly attractive as a cancer therapy, because it does not harm healthy tissues when it is administered properly. this could make it a useful alternative to other chemotherapies .
celtic biotech has been researching snake venom since 2003 and holds several patents, according to the irish times .
we were thinking this should have occurred to the irish before st. patrick kicked out all the snakes .
many products featured on this site were editorially chosen. popular science may receive financial compensation for products purchased through this site .
copyright © 2018 popular science. a bonnier corporation company. all rights reserved. reproduction in whole or in part without permission is prohibited .
next time we write about any of these organizations, we' ll email you a link to the story. you may edit your settings or unsubscribe at any time .
thank you for signing up for vaccine news alerts! please select the organizations you wish to subscribe to .
we will email you whenever we publish an article about these organizations. you may update or cancel your subscription at any time .
by signing up for alerts, you agree to the privacy policy & terms of service .
mr. krohn has over three decades of operating and leadership experience across diverse industry sectors. his expertise includes corporate financial management, strategic financial advisory, private and public equity and debt financing, and m & a strategy and execution .
mr. pim, cpa, has three decades of financial and business development experience. his expertise extends to auditing, financial reporting, sec compliance, strategic planning, risk management, and m & a activity .
dr. laff earned his b. s. in biology and ph. d. in molecular cell biology at yale university, where he received the sterling prize fellowship. he continued his training as a postdoctoral research scientist at harvard medical school. dr. laff’s eclectic career in the life sciences has included venture capital, buy - side equity analysis, competitive intelligence, business development, market research, and medical communications .
at a boston - based venture capital fund, dr. laff sourced, vetted and managed investments in early - stage life sciences companies. in this role, he advised portfolio company executives on financial, strategic and technical matters and contributed actively to discussion and decision making at board of directors meetings. as a biotechnology analyst at several long / short equity hedge funds, he generated timely risk assessments and trading recommendations, mapped the competitive landscape for disease - and technology - specific markets, and conducted comprehensive due diligence to support his investment theses .
stay current on our sec filings, events, news and more. sign up now
last updated: jul 9, 2018 2: 32 p. m. edt
have watchlists? log in to see them here or sign up to get started .
by using this site you agree to the terms of service, privacy policy, and cookie policy .
intraday data provided by six financial information and subject to terms of use. historical and current end - of - day data provided by six financial information. all quotes are in local exchange time. real - time last sale data for u. s. stock quotes reflect trades reported through nasdaq only. intraday data delayed at least 15 minutes or per exchange requirements .
news corp is a network of leading companies in the worlds of diversified media, news, education, and information services .
p / e ratio (ttm) the price to earnings (p / e) ratio, a key valuation measure, is calculated by dividing the stock' s most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period. earnings per share (ttm) a company' s net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. market capitalization reflects the total market value of a company. market cap is calculated by multiplying the number of shares outstanding by the stock' s price. for companies with multiple common share classes, market capitalization includes both classes. shares outstanding number of shares that are currently held by investors, including restricted shares owned by the company' s officers and insiders as well as those held by the public. public float the number of shares in the hands of public investors and available to trade. to calculate, start with total shares outstanding and subtract the number of restricted shares. restricted stock typically is that issued to company insiders with limits on when it may be traded. dividend yield a company' s dividend expressed as a percentage of its current stock price .
shares sold short the total number of shares of a security that have been sold short and not yet repurchased. change from last percentage change in short interest from the previous report to the most recent report. exchanges report short interest twice a month. percent of float total short positions relative to the number of shares available to trade .
money flow uptick / downtick ratio money flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an
uptick
in price and the value of trades made on a
downtick
in price. the up / down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. net money flow is the value of uptick trades minus the value of downtick trades. our calculations are based on comprehensive, delayed quotes .
real - time u. s. stock quotes reflect trades reported through nasdaq only .
international stock quotes are delayed as per exchange requirements. indexes may be real - time or delayed; refer to time stamps on index quote pages for information on delay times .
quote data, except u. s. stocks, provided by six financial information .
data is provided
as is
for informational purposes only and is not intended for trading purposes. six financial information (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. data may be intentionally delayed pursuant to supplier requirements .
© thomson reuters. all rights reserved. any copying, republication or redistribution of lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of lipper. lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon .
but what does it take to be truly innovative? well, innovative organisations tend to have a strong learning culture in place. they give their people the time and space to think differently. they also incentivise their people based on the outcomes they achieve, rather than the work they do, so that they have the freedom to take a fresh approach to old challenges. finally, they put in place processes to enable their people to take their ideas to market .
cultural challenges can be an obstacle to ceos, but what else is stopping them from being more innovative? according to our research, nearly half (43 %) of ceos are being held back by a lack of financial resources while 30% are struggling to find the right talent .
© 2017 - mon jul 09 12: 43: 51 edt 2018 pwc. all rights reserved. pwc refers to the pwc network and / or one or more of its member firms, each of which is a separate legal entity. please see urltoken for further details .
racine, wis. , april 18, 2017 – on june 8, the 150th birthday of famed architect frank lloyd wright will be celebrated, and design enthusiasts around the world are preparing for special events to commemorate and honor one of america’s most innovative architects .
less than an hour from milwaukee, wisconsin, the sc johnson world headquarters is home to two frank lloyd wright - designed buildings—the administration building (opened in 1939) and the research tower (opened in 1950). both buildings are on the national register of historic places and open to the public for free tours .
“for almost 80 years, the frank lloyd wright - designed buildings at sc johnson’s global headquarters have served as a source for inspiration for all who visit, ” said kelly m. semrau, senior vice president - global corporate affairs, communication and sustainability, sc johnson. “the research tower is an important part of our company’s legacy. we’re proud of our history and of the opportunity to share it with the public. ”
the company is committed to preserving the history of its wright - designed treasures. in 2013, the research tower went through an extensive 12 - month restoration, which involved both exterior and interior updates. the research tower was opened for free public tours in spring 2014 .
more than 7, 000 pyrex glass tubes are featured throughout the tower to construct the building’s numerous windows. if the glass tubes in the tower were laid end to end they would span 17 miles, roughly the size of 586 stacked research towers .
when it opened, there was nothing in place to shade the building from light. it is said that it was so bright in the early days that scientists were issued sunglasses until window shades could be installed .
there are 15 stories and 232 stairs. the tower consists of a series of square floors accompanied by round mezzanine levels. the mezzanine levels were not enclosed, which allowed for easier communication between the scientists .
the research tower is one of the tallest structures ever built on the cantilever principle. it stands 153 feet tall and its central core, which is 13 feet in diameter, extends 54 feet into the ground. all 15 floors of the research tower are supported by the “taproot” core; much like a tree supports its branches.
spotlight innovation inc. ( otcqb : stlt ) is a united states pharmaceutical holding company that identifies and acquires early stage pharmaceutical companies that are developing unique intellectual property often in academic settings . the company currently maintains two subsidiaries : memcine pharmaceuticals , inc. and celtic biotech iowa , inc . spotlight innovation inc. is based in west des moines , iowa and is publicly traded on the otcqb marketplace under the stock ticker symbol , stlt .
spotlight innovation inc. (otcqb: stlt) is a united states pharmaceutical holding company that identifies and acquires early stage pharmaceutical companies that are developing unique intellectual property often in academic settings. the company currently maintains two subsidiaries: memcine pharmaceuticals, inc. and celtic biotech iowa, inc. spotlight innovation inc. is based in west des moines, iowa and is publicly traded on the otcqb marketplace under the stock ticker symbol, stlt.
spotlight innovation inc. (otcqb: stlt) is a united states pharmaceutical holding company that identifies and acquires early stage pharmaceutical companies that are developing unique intellectual property often in academic settings. the company currently maintains two subsidiaries: memcine pharmaceuticals, inc. and celtic biotech iowa, inc. spotlight innovation inc. is based in west des moines, iowa and is publicly traded on the otcqb marketplace under the stock ticker symbol, stlt.